title: [Possible therapeutic intervention with inhibitors and promoters of phospholipase A2 subtypes].
abstract: Phospholipase A2 (PLA2) is a group of enzymes discovered more than a century ago in insect and snake poison. Not more than 20 years ago they were identified in vertebrates, and during the last five years, research has accelerated in relation to isolating and cloning several members of this super-family in humans. PLA2 inhibitors are in the process of being developed for pharmaceutical use. The purpose of this review is to outline the relevance and prospectives of PLA2 in a clinical perspective.
authors.affiliation: Københavns Universitet, Øjenpatologisk Institut. mkolko@dadlnet.dk
authors.forename: Miriam
authors.initials: M
authors.lastname: Kolko
authors.forename: Chen
authors.initials: C
authors.lastname: Zhan
authors.forename: Jens Rovelt
authors.initials: JR
authors.lastname: Andreasen
authors.forename: Jan Ulrik
authors.initials: JU
authors.lastname: Prause
authors.forename: Steffen
authors.initials: S
authors.lastname: Heegaard
mesh_terms: D001927:Brain Diseases / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2
chemical_list: D004791:Enzyme Inhibitors; D010741:Phospholipases A; D054467:Phospholipases A2